Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Jemperli

(Dostarlimab)

ApprovedMonoclonal antibody

GGlaxo Dba Glaxosmithkline

Dostarlimab is used to treat certain types of cancer, specifically endometrial cancer (cancer of the uterus lining) that has a specific genetic marker called mismatch repair deficiency. It works by helping the immune system recognize and attack cancer cells.[2] Jemperli is currently approved and in use across 33 indications[4].[1]

Jemperli is one of 522 small molecule programs targeting Pancreatic Cancer. It is currently in Approved.

33

Indications

77

Total Trials

53

Active Trials

521

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pancreatic CancerCompleted

Endometrium NeoplasmUnknown

Endometrial CarcinomaUnknown

Colon CancerRecruiting

Metastatic CancerRecruiting

Locally-Advanced Rectal CancerRecruiting

Ovarian Clear Cell CarcinomaRecruiting

Neoplasms, Head and NeckActive, not recruiting

Lung Cancer (non-Small Cell)Active, not recruiting

Tumours, GynecologicalRecruiting

Pancreatic CancerPhase 2

Completed

Endometrium NeoplasmPreclinical

Unknown

Endometrial CarcinomaPreclinical

Unknown

Colon CancerPhase 3

Recruiting

Metastatic CancerPhase 2

Recruiting

Locally-Advanced Rectal CancerPhase 3

Recruiting

Ovarian Clear Cell CarcinomaPreclinical

Recruiting

Neoplasms, Head and NeckPhase 2

Active, not recruiting

Lung Cancer (non-Small Cell)Phase 3

Active, not recruiting

Tumours, GynecologicalPreclinical

Recruiting

Showing 10 of 33 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Jemperli

GGlaxo Dba Glaxosmithkline

Adenocard

Lexiscan

Voltaren

Zolymbus

Methylthioninium Chloride

PProvepharm SAS

MS Contin

HHikma Pharmaceuticals LLC

Duragesic-100

MS Contin

HHikma Pharmaceuticals LLC

Sporanox

SSebela Pharmaceuticals Development LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Pediatric

NCT06521567

Phase 3Active, not recruiting

Endometrial Cancer

NCT03981796

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT04446351

Q1 2027

Post-ApprovalNot yet recruiting

Endometrial Cancer

NCT06897527

Phase 2Recruiting

Endometrial Cancer

NCT04774419

Phase 2Active, not recruiting

Lung Cancer

NCT05565378

Clinical

Trials by Indication[1]

Endometrial Cancer10 trials

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

Not yet recruiting·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT07013851·25 enrolled

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06317311·41 enrolled

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05819892·21 enrolled

Show 7 more trials

pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer

Not yet recruiting·UUniversity College, London·Phase 2·NCT07115927·40 enrolled

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Active, not recruiting·TTesaro, Inc.·Phase 3·NCT03981796·785 enrolled

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Not yet recruiting· GSK logo

GSK·Phase 4·NCT06897527·100 enrolled

DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer

Unknown status·GGrupo Español de Investigación en Cáncer de Ovario··NCT05728814·100 enrolled

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Recruiting· GSK logo

GSK·Phase 2·NCT07108270·30 enrolled

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Active, not recruiting·AARCAGY/ GINECO GROUP·Phase 3·NCT05201547·260 enrolled

Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04774419·62 enrolled

Locally-advanced Rectal Cancer4 trials

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Recruiting·—·Phase 3·NCT06762405·68 enrolled

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

Recruiting·NNational Cancer Institute, Naples··NCT07269249·50 enrolled

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT05723562·154 enrolled

Show 1 more trial

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06640049·23 enrolled

Ovarian Cancer4 trials

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT05065021·40 enrolled

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

Terminated·TTesaro, Inc.·Phase 2·NCT03955471·41 enrolled

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Completed·TTesaro, Inc.·Phase 2·NCT05751629·41 enrolled

Show 1 more trial

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Active, not recruiting·TTesaro, Inc.·Phase 3·NCT03602859·1,400 enrolled

Colon Cancer3 trials

Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT06830239·10 enrolled

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT05855200·892 enrolled

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Recruiting·UUniversity of Iowa·Phase 2·NCT05239546·25 enrolled

Advanced Solid Tumors3 trials

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04446351·107 enrolled

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Active, not recruiting·IiTeos Belgium SA·Phase 1/2·NCT05060432·153 enrolled

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Completed·TTesaro, Inc.·Phase 1·NCT03250832·111 enrolled

40 more indications

Head and Neck Squamous Cell Carcinoma3 trials

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT07408063·30 enrolled

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 1/2·NCT05784012·34 enrolled

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting· GSK logo

GSK·Phase 3·NCT06256588·864 enrolled

Non-Small Cell Lung Cancer3 trials

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Completed· GSK logo

GSK·Phase 2·NCT06926673·62 enrolled

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed· GSK logo

GSK·Phase 2·NCT03739710·175 enrolled

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Terminated· GSK logo

GSK·Phase 2·NCT04581824·243 enrolled

Lung Cancer (Non-Small Cell)3 trials

A Pilot/Exploratory Translational Study to Evaluate Response to Dostarlimab and Pembrolizumab in Extracellular Vesicles (EVs) or Patient-derived Organoids (PDOs) and by Zirconium-89 Labelled Programmed Death Ligand 1 Positron Emission Tomography in Participants With Recurrent Non-small Cell Lung Cancer

Terminated· GSK logo

GSK·Preclinical·NCT06405230·2 enrolled

A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)

Active, not recruiting· GSK logo

GSK·Phase 3·NCT06472076·88 enrolled

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

Active, not recruiting· GSK logo

GSK·Preclinical·NCT04655976·758 enrolled

Neoplasms3 trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Active, not recruiting·TTesaro, Inc.·Phase 1·NCT02715284·729 enrolled

A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

Terminated· GSK logo

GSK·Phase 1·NCT03843359·97 enrolled

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT05277051·152 enrolled

Efficacy and Safety2 trials

Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

Withdrawn·VVall d'Hebron Institute of Oncology·Phase 1/2·NCT06385548

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT04779151·51 enrolled

Pancreatic Cancer2 trials

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT04409002·18 enrolled

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

Recruiting·HHopital Foch·Phase 2·NCT06757244·35 enrolled

Breast Cancer2 trials

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Active, not recruiting·—·Phase 2·NCT04584255·62 enrolled

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04837209·32 enrolled

Lung Cancer2 trials

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT05565378·351 enrolled

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Active, not recruiting·IiOnctura·Phase 1/2·NCT06879717·45 enrolled

Metastatic2 trials

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04387084·10 enrolled

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Active, not recruiting·TTrisha Wise-Draper·Phase 2·NCT04313504·23 enrolled

Metastatic Cancer1 trial

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Recruiting·UUNICANCER·Phase 2·NCT06333314·120 enrolled

Primary Peritoneal Cancer1 trial

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT04679064·427 enrolled

Serous Carcinoma1 trial

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Active, not recruiting·CCasey Cosgrove·Phase 2·NCT05870761·8 enrolled

Colorectal Cancer1 trial

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Withdrawn·IIbrahim Halil Sahin·Phase 2·NCT06365970

Cancers1 trial

PREventing Second Cancers With DOSTARlimab

Recruiting·CCentre Leon Berard·Phase 2·NCT05855811·400 enrolled

Pediatric1 trial

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Active, not recruiting· GSK logo

GSK·Phase 1/2·NCT06521567·83 enrolled

Solid Tumors1 trial

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Terminated· GSK logo

GSK·Phase 1·NCT04544995·47 enrolled

Monotherapy1 trial

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Terminated· GSK logo

GSK·Phase 1/2·NCT06655818·4 enrolled

Treatment1 trial

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Withdrawn·AAGO Research GmbH·Phase 2·NCT05126342

Clear Cell Carcinoma1 trial

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Recruiting·YYonsei University·Phase 2·NCT06023862·198 enrolled

Cervical Cancer1 trial

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Active, not recruiting·MMeghan Shea·Phase 2·NCT06238635·66 enrolled

Neuroendocrine Carcinoma1 trial

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04701307·48 enrolled

Cholangiocarcinoma1 trial

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Withdrawn·—·Phase 2·NCT04895046

Brain Metastases1 trial

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05700721·120 enrolled

Selected Advanced Solid Tumors1 trial

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed· GSK logo

GSK·Phase 1·NCT02723955·829 enrolled

Locally Advanced Rectal Cancer (LARC)1 trial

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

Not yet recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT07381777·270 enrolled

Melanoma1 trial

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Active, not recruiting·DDiwakar Davar·Phase 2·NCT04139902·48 enrolled

Multiple Myeloma1 trial

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active, not recruiting· GSK logo

GSK·Phase 2·NCT04126200·208 enrolled

Penile Carcinoma1 trial

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05526989·25 enrolled

Patients With Solid Tumors1 trial

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Terminated·EElevation Oncology·Phase 1·NCT05980416·88 enrolled

Microsatellite Stable1 trial

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Recruiting· GSK logo

GSK·Phase 2·NCT06567782·120 enrolled

Progressive Cervix Cancer1 trial

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Active, not recruiting·UUniversity of Oklahoma·Phase 2·NCT04068753·66 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer

Completed·MMayo Clinic·Phase 2·NCT04493060·22 enrolled

Adenocarcinoma1 trial

Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT06059495·89 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

Active, not recruiting·UUniversity of Washington·Phase 1·NCT04673448·18 enrolled

Female1 trial

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma (DICER Trial): Taiwanese Gynecologic Oncology Group (TGOG) 1012

Recruiting·CChang Gung Memorial Hospital·Phase 2·NCT07336147·45 enrolled

Tumours, Gynecological1 trial

A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Preclinical·NCT06796907·305 enrolled

Rectal Neoplasms1 trial

A Phase 1b/2 Trial of Preoperative Niraparib, Dostarlimab, and Hypofractionated Radiotherapy for the Treatment of Locally-advanced Rectal Cancers.

Terminated·UUniversity of Iowa·Phase 1·NCT04926324·3 enrolled

Neoplasms, Head and Neck1 trial

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06062420·316 enrolled

Ovarian Clear Cell Carcinoma1 trial

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06065462·21 enrolled

Unspecified1 trial

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Withdrawn·UUniversity of Miami·Phase 2·NCT05405192

Regulatory

FDA Approval Timeline[5]

Apr 22, 2021

JEMPERLI

BLA BLA761174

Sources

References

[1]
ClinicalTrials.gov — 77 trial records for Dostarlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jemperli drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dostarlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dostarlimab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761174). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Antagonist[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Related News